UK spin‑out speeds up development and reduces animal testing

Boehringer Ingelheim reports significant reductions in weight

Partnership to support selection of first neoantigen therapy candidate

Collaboration aims to create integrated platform from discovery to IND submission

Lead asset shows systemic, dose‑dependent anti‑tumour activity

US study marks company’s second clinical trial of ovarian cancer therapy

Clesrovimab is first monoclonal antibody offering a single fixed dose for infants

Greater flexibility for people with systemic lupus erythematosus

Company expects two‑year dfs data by q1 2028

New authorisation offers additional option for patients with lvef ≥40%